These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17802913)
1. Acquired AmpC type beta-lactamases: an emerging problem in Italian long-term care and rehabilitation facilities. Migliavacca R; Nucleo E; D'Andrea MM; Spalla M; Giani T; Pagani L New Microbiol; 2007 Jul; 30(3):295-8. PubMed ID: 17802913 [TBL] [Abstract][Full Text] [Related]
2. CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. D'Andrea MM; Nucleo E; Luzzaro F; Giani T; Migliavacca R; Vailati F; Kroumova V; Pagani L; Rossolini GM Antimicrob Agents Chemother; 2006 Feb; 50(2):618-24. PubMed ID: 16436718 [TBL] [Abstract][Full Text] [Related]
3. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415 [TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy. Migliavacca R; Migliavacca A; Nucleo E; Ciaponi A; Spalla M; De Luca C; Pagani L New Microbiol; 2007 Jul; 30(3):362-6. PubMed ID: 17802927 [TBL] [Abstract][Full Text] [Related]
5. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia. Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339 [TBL] [Abstract][Full Text] [Related]
7. Four variants of the Citrobacter freundii AmpC-Type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. Literacka E; Empel J; Baraniak A; Sadowy E; Hryniewicz W; Gniadkowski M Antimicrob Agents Chemother; 2004 Nov; 48(11):4136-43. PubMed ID: 15504832 [TBL] [Abstract][Full Text] [Related]
8. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF]. Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of SXT/R391-like integrative and conjugative elements carrying blaCMY-2 in Proteus mirabilis. Mata C; Navarro F; Miró E; Walsh TR; Mirelis B; Toleman M J Antimicrob Chemother; 2011 Oct; 66(10):2266-70. PubMed ID: 21752830 [TBL] [Abstract][Full Text] [Related]
10. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases. Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital. Briñas L; Lantero M; de Diego I; Alvarez M; Zarazaga M; Torres C J Antimicrob Chemother; 2005 Dec; 56(6):1107-10. PubMed ID: 16239288 [TBL] [Abstract][Full Text] [Related]
12. Differences in biofilm formation and aggregative adherence between beta-lactam susceptible and beta-lactamases producing P. mirabilis clinical isolates. Nucleo E; Fugazza G; Migliavacca R; Spalla M; Comelli M; Pagani L; Debiaggi M New Microbiol; 2010 Jan; 33(1):37-45. PubMed ID: 20402412 [TBL] [Abstract][Full Text] [Related]
14. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Tan TY; Ng SY; Teo L; Koh Y; Teok CH J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079 [TBL] [Abstract][Full Text] [Related]
15. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis. Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101 [No Abstract] [Full Text] [Related]
16. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates. Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241 [TBL] [Abstract][Full Text] [Related]
17. Extended-spectrum {beta}-lactamases and AmpC {beta}-lactamases in ceftiofur-resistant Salmonella enterica isolates from food and livestock obtained in Germany during 2003-07. Rodríguez I; Barownick W; Helmuth R; Mendoza MC; Rodicio MR; Schroeter A; Guerra B J Antimicrob Chemother; 2009 Aug; 64(2):301-9. PubMed ID: 19474065 [TBL] [Abstract][Full Text] [Related]
18. Emergence and prevalence of beta-lactamase-producing Klebsiella pneumoniae resistant to cephems in Japan. Muratani T; Kobayashi T; Matsumoto T Int J Antimicrob Agents; 2006 Jun; 27(6):491-9. PubMed ID: 16701983 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital. Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475 [TBL] [Abstract][Full Text] [Related]
20. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]